Abstract
Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Crisaborole ointment 2% was generally well tolerated in the short-term studies, with its favorable safety profile maintained over the longer term (up to 52 weeks) in a multicentre, extension study. Most treatment-emergent adverse events (TEAEs) were of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option fo...Continue Reading
References
Jan 17, 2007·The British Journal of Dermatology·J CallenB U Wintroub
Mar 24, 2009·Bioorganic & Medicinal Chemistry Letters·Tsutomu AkamaJacob J Plattner
Jun 16, 2010·Annals of Dermatology·Thomas Bieber
Jul 31, 2012·FEBS Letters·Yvonne R FreundYasheen Zhou
Sep 7, 2012·The Journal of Allergy and Clinical Immunology·Julia K GittlerEmma Guttman-Yassky
Oct 17, 2012·Seminars in Cutaneous Medicine and Surgery·Charles N EllisLawrence F Eichenfield
Feb 5, 2013·The Journal of Allergy and Clinical Immunology·Lynda SchneiderDana Wallace
Apr 4, 2013·Paediatric Drugs·Warner W Carr
Dec 3, 2013·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
May 13, 2014·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
May 20, 2016·Pediatric Dermatology·Lee T ZaneAdelaide A Hebert
Jun 24, 2016·American Journal of Clinical Dermatology·Lee T ZaneSepehr Shakib
Jul 3, 2016·American Journal of Clinical Dermatology·Diane Wang, Lisa A Beck
Jul 16, 2016·Journal of the American Academy of Dermatology·Amy S PallerAdelaide A Hebert
Aug 16, 2016·Seminars in Cutaneous Medicine and Surgery·Lawrence F EichenfieldAlan D Irvine
Apr 10, 2017·The Journal of Allergy and Clinical Immunology·Lawrence F EichenfieldMark Boguniewicz
Aug 22, 2017·Journal of the American Academy of Dermatology·Lawrence F EichenfieldEduardo Tschen
Citations
May 5, 2018·Expert Opinion on Therapeutic Patents·Alessio NocentiniJean-Yves Winum
Dec 28, 2018·Expert Review of Clinical Immunology·Aisleen Diaz, Emma Guttman-Yassky
Apr 20, 2019·Expert Opinion on Pharmacotherapy·Vignesh RamachandranLindsay C Strowd
Mar 10, 2020·Clinical Science·Ryan P Ceddia, Sheila Collins
Jun 13, 2018·Journal of Food Science and Technology·Yu-Pei ChenLeong-Perng Chan
Nov 7, 2019·Children·Travis FrantzSteven R Feldman
Jan 3, 2019·Expert Opinion on Pharmacotherapy·Katelyn R GlinesSteven R Feldman
Dec 15, 2020·Dermatologic Therapy·Nafise YazdanianAzadeh Goodarzi
Feb 14, 2021·Indian Journal of Dermatology, Venereology and Leprology·Anupam DasBhushan Madke
Jan 13, 2021·Scientific Reports·Keimon SayamaTakatoshi Murase
Aug 25, 2019·Bioorganic Chemistry·Krzysztof M BorysAgnieszka Adamczyk-Woźniak
Mar 5, 2021·Pharmacology & Therapeutics·Xiaoliang YangKenji Kabashima
Apr 22, 2021·Clinical Ophthalmology·Crystal X HuangJoanne F Shen
May 28, 2021·Journal of Medicinal Chemistry·Jiyun SunSteven H Liang
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Paolo Saul CoghiYingjun Zhang
Jul 22, 2021·The British Journal of Dermatology·H SaekiH Tsubouchi
Oct 29, 2021·Journal of the American Academy of Dermatology·Hidehisa SaekiHidetsugu Tsubouchi